GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Anthem Biosciences ANTHEM.NS · INR

Health Care · NSE · 🇮🇳 India

Compare

958.15

+4.65%

Close of 9 Nov 2026, in INR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Anthem Biosciences

Its shares trade on NSE under the ticker ANTHEM.NS. It has been listed since 21 July 2025. In the fiscal year to 31 March 2026, it reported revenue of ₹21.24bn and net income of ₹5.92bn. At that date it held total assets of ₹34.29bn and shareholders' equity of ₹30.43bn.

Anthem BioSciences Ltd. engages in contract research, development and manufacturing, and organization with fully integrated operations spanning across drug discovery, development and manufacturing. The company is headquartered in Bangalore, Karnataka. The company went IPO on 2025-07-21. The firm helps new and established biotech’s and big pharma, develop, optimize and test proteins, monoclonal antibodies, peptides, large molecules, small molecules, toxins and much more. In addition to product research and development, it helps test drugs for safety, efficacy (in vitro and in vivo), pre-clinical animal studies in a GLP facility, clone development, antibody drug conjugates, research and development and manufacture of highly potent compounds, flow chemistry-based production and large-scale commercial product manufacture. Its product line includes human nutrition, animal health, and industrial products. Under human nutrition, it offers active pharmaceutical ingredients, dietary supplements, probiotics, and enzymes, among others.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Life Sciences Tools & Services
Listed since
21 Jul 2025
Employees
2,062

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Anthem Biosciences operates fully integrated contract research and manufacturing services.
  • The company employs 2,062 full-time staff in Bangalore, India.
  • It serves both new biotechs and established big pharma clients.

Weaknesses

  • The firm recently completed its IPO on July 21, 2025.
  • Financial data for the site is not explicitly provided in the source.
  • Reliance on a single recent public listing may limit historical depth.

Opportunities

  • The company supports development of proteins, antibodies, and peptides.
  • It offers safety and efficacy testing in GLP facilities.
  • Product lines include human nutrition and animal health solutions.

Threats

  • The source description is treated as untrusted facts.
  • Regulatory changes could impact pre-clinical animal studies.
  • Competition exists within the life sciences tools and services sector.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.